Dryvax Side Effects
Generic Name: smallpox vaccine
Note: This page contains information about the side effects of smallpox vaccine. Some of the dosage forms included on this document may not apply to the brand name Dryvax.
Not all side effects for Dryvax may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to smallpox vaccine: injection powder for solution, injection powder for suspension
In addition to its needed effects, some unwanted effects may be caused by smallpox vaccine (the active ingredient contained in Dryvax). In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking smallpox vaccine:More common
- Feeling unusually cold
- swollen, painful, or tender lymph glands in the neck, armpit, or groin
- back pain
- blistering, peeling, or loosening of skin
- blue or pale skin
- blurred vision
- changes in vision
- chest discomfort
- chest pain, possibly moving to the left arm, neck, or shoulder
- convulsions (seizures)
- difficult or labored breathing
- fast heartbeat
- fever and chills
- joint or muscle pain
- loss of consciousness
- mood or mental changes
- red skin lesions, often with a purple center
- red, irritated eyes
- shortness of breath
- skin rash that is encrusted, scaly, and oozing
- sore throat
- sores, ulcers, or white spots in the mouth or on the lips
- stiff neck
- tightness in the chest
- trouble breathing
- unusual tiredness or weakness
Some of the side effects that can occur with smallpox vaccine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Decreased ability to exercise
- difficulty having a bowel movement (stool)
- difficulty with moving
- flushing or redness of the skin
- general feeling of discomfort or illness
- itching, pain, redness, or swelling at the vaccine site
- muscle aching or cramping
- muscle stiffness
- swollen joints
- unusually warm skin
For Healthcare Professionals
Applies to smallpox vaccine: percutaneous powder for injection
Regional lymphadenopathy, myalgia, fever, nausea, and malaise occur at the height of the major reaction after vaccination, indicating the vaccination was successful. Fever commonly occurs in children after vaccination but is less common in adults. From 4 to 14 days after primary vaccination at least 70% of children have had 1 or more days of temperature greater than 100 degrees F. Fifteen to twenty percent have had temperatures greater than 102 degrees F.[Ref]
The most frequent complication is inadvertent inoculation of other sites, usually due of autoinoculation of the virus transferred from the vaccination site to other parts of the body. The face, eyelids, nose, mouth, genitalia, and rectum are most commonly involved. Autoinoculation of the eyes may cause blindness.[Ref]
Postvaccinial encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia (vaccinia necrosum) and eczema vaccinatum are more severe complications that may occur following primary vaccination or revaccination. Severe disability, permanent neurological sequelae, and/or death may occur. Approximately 1 death per million primary vaccinations and 1 death per 4 million revaccinations have been reported, most often due to encephalitis or progressive vaccinia. Death has also occurred in unvaccinated contacts of vaccinated persons. Vaccinia viremia has been rarely reported after vaccination.
Vaccinia Immune Globulin may be indicated for certain vaccine complications such as eczema vaccinatum, progressive vaccinia, severe generalized vaccinia, or severe ocular vaccinia and may be obtained from the Centers for Disease Control (CDC). Physicians may contact the CDC for assistance with diagnosis and treatment of smallpox vaccine complications. Telephone: (404) 639-3670 (Monday-Friday, 8 AM-4:30 PM EST) or (404) 639-2888 (at other times).[Ref]
Healthy persons may develop generalized vaccinia with a generally self-limited vesicular or maculopapular rash within 6 to 9 days after vaccination. This condition is more serious in immunocompromised individuals.
Eczema vaccinatum appears shortly after the vaccinial lesion appears and is characterized by a high fever, malaise, generalized lymphadenopathy, and extensive vesicular and pustular eruptions. Patients with a history of atopic dermatitis have the highest risk of developing EV. The prognosis is poor and the mortality rate is high.
Progressive vaccinia (i.e., vaccinia necrosum, vaccinia gangrenosa, prolonged vaccinia, disseminated vaccinia), is characterized by a nonhealing vaccination site, painless progressive necrosis at the vaccination site, and occasionally metastasis to other parts of the skin, bones, and viscera. The distant lesions contain live vaccinia virus. Immunocompromised patients are at a greater risk. The prognosis is poor.
Vaccinia Immune Globulin (VIG) may be indicated for eczema vaccinatum or progressive vaccinia and may be obtained from the Centers for Disease Control (CDC). Physicians may contact the CDC for assistance with diagnosis and treatment of smallpox vaccine (the active ingredient contained in Dryvax) complications. Telephone: (404) 639-3670 (Monday-Friday, 8 AM-4:30 PM EST) or (404) 639-2888 (at other times).
Hypersensitivity reactions including Stevens-Johnson syndrome and erythema multiforme have rarely been reported. The onset of symptoms (bulls-eye lesions and pruritus) is generally 10 days after vaccination.
Dermatofibrosarcoma protuberans, malignant fibrous histiocytoma, malignant melanoma, squamous cell carcinoma, basal cell carcinoma, and benign dermatofibroma have been reported in smallpox vaccination scars.
Contact spread of vaccinia from recently vaccinated military personnel has been reported.[Ref]
Dermatologic side effects have included pruritus, rash, generalized vaccinia (GV), eczema vaccinatum (EV), progressive vaccinia (PV), erythema multiforme, folliculitis, Stevens-Johnson syndrome, bacterial infections, and contact spread. In addition, precipitation of erythema nodosum in patients with leprosy, malignant tumors at the vaccination scar, discoid lupus, and localized myxedema have been reported; however, causality has not been established.[Ref]
Local side effects have included secondary pyogenic infections at the site of vaccine application. occurring approximately 5 days after vaccination. Swelling, warmth, and pain at the injection site, with peak symptoms occurring 8 to 10 days after vaccination and resolving within 24 to 72 hours, are indicative of a normal vaccination reaction.[Ref]
Hypersensitivity reactions may include persistent allergic sensitization to viral proteins even after immunity has waned. The allergy is manifested by the appearance of a papule and a small area of redness appearing within the first 24 hours after revaccination. Vesicles may appear in 24 to 48 hours, followed by scabbing. Stevens-Johnson syndrome, and erythema multiforme have also been reported.[Ref]
Ocular side effects have included mild to severe ocular vaccinia resulting from inadvertent autoinoculation and manifested by keratitis (epithelial and stromal), iritis, conjunctivitis (hyperemia, edema, membranes, focal lesions), and/or blepharitis (lid pustules, edema, hyperemia, cellulitis). Corneal scarring, disciform edema, and loss of vision have occurred in patients with vaccinial keratitis. Lymphadenopathy and fever have also been associated with ocular vaccinia. Ocular vaccinia has been reported in contacts of vaccinees.[Ref]
Trifluridine or vidarabine ophthalmic ointment have been recommended for conjunctival or corneal vaccinia infections. In addition, vaccinia immune globulin (VIG) may be considered for severe blepharitis, blepharoconjunctivitis, or keratitis (if there is a risk of vision loss). When using of VIG for keratitis, the possibility of an increased risk of corneal scar formation (associated with large doses over multiple days in animal models) should be taken into consideration. VIG is not recommended for isolated keratitis.
VIG may be obtained from the Centers for Disease Control (CDC). Physicians may contact the CDC for assistance with diagnosis and treatment of smallpox vaccine complications. Telephone: (404) 639-3670 (Monday-Friday, 8 AM-4:30 PM EST) or (404) 639-2888 (at other times).[Ref]
Nervous system side effects have rarely included headache, dizziness, paresthesia, vertigo, transient global amnesia, anoxic encephalopathy, polyneuropathy, cerebrovascular accident, CNS tumor, precipitation of neuritis in leprosy patients, transverse myelitis, seizures, paralysis, polyneuritis, brachial neuritis, and one case of ptosis, diplopia, slurred speech, and paresis, although causality has not been clearly established in all cases. The vaccine has also been associated with encephalitis (PVE) and encephalomyelitis (PVEM). PVE is has a sudden onset (6 to 10 days after vaccination) and is characterized by seizures, hemiplegia, aphasia, transient amnesia, generalized cerebral edema, mild lymphocytic meningeal infiltration, ganglion degenerative changes, and perivascular hemorrhages. Cerebrospinal fluid examination may demonstrate increased opening CSF pressure, monocytosis, lymphocytosis, or elevated CSF protein. PVEM is characterized by sudden onset (11 to 15 days after vaccination) of fever, headache, malaise, lethargy, vomiting, and anorexia. Symptoms may progress to unconsciousness, amnesia, confusion, disorientation, restlessness, delirium, drowsiness, seizures, urinary incontinence, urinary retention, constipation, meningismus and/or coma. Increased CSF pressure is present, but chemistry and cell count may be normal. Histopathological changes include perivenous demyelination, microglial proliferation in demyelinated areas with lymphocytic infiltration.[Ref]
PVE occurs more commonly in children less than 2 years old. The incidence in 1968 was reported as 2.9 cases per million vaccinees. The mortality rate is 25%, complete recovery occurs in 50%, and neurologic sequelae remain in 25%.[Ref]
Cardiovascular side effects have rarely included myocarditis, pericarditis, myocardial infarction, hypertension, atypical chest pain, angina, palpitations, supraventricular tachycardia, atrial dysrhythmias, symptomatic trigeminy, premature ventricular contractions, coronary artery disease, dilated cardiomyopathy, sudden death due to atherosclerotic coronary artery disease 60 days after vaccination, and chest tightness with ECG changes, although causality has not been clearly established in all cases.[Ref]
Symptoms of myopericarditis include chest pain, ECG changes, increased cardiac enzymes, and sometimes abnormal echocardiograms, and usually occur 4 to 30 days after vaccination.
Pulmonary edema and eosinophilic myopericarditis developed in a 29-year-old male 3 weeks after multiple vaccinations including smallpox vaccine.[Ref]
Musculoskeletal side effects have included osteomyelitis, arthritis, shoulder pain, and noncardiac chest pain; however, causality has not been established in all cases.[Ref]
Respiratory side effects have rarely included asthma, pneumonia, respiratory distress, and pseudomediastinum associated with scuba diving, although causality has not been clearly established.[Ref]
Genitourinary side effects have rarely included prostatitis, although causality has not been clearly established.[Ref]
Gastrointestinal side effects have rarely included cholecystitis and gastroesophageal reflux disease, although causality has not been clearly established in all cases.[Ref]
1. "Smallpox vaccination and adverse reactions: guidance for clinicians." MMWR Morb Mortal Wkly Rep 52 (2003): 1-29
2. Melenovsky V, Stulc T, Kozich V, et al. "Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine." Am Heart J 146 (2003): 110
3. "From the Center of Disease Control and Prevention. Smallpox vaccine adverse events among civilians--United States, January 24-February 18, 2003." JAMA 289 (2003): 1497-8
4. Grabenstein JD, Winkenwerder W Jr "US Military Smallpox Vaccination Program Experience." JAMA 289 (2003): 3278-82
5. "Smallpox vaccine adverse events among civilians--United States, February 25-March 3, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 180-1, 191
6. Rotz LD, Damon IK, Becher JA "Vaccinia (smallpox) vaccine recommendations of the advisory committee on immunization practices (ACIP)." MMWR Morb Mortal Wkly Rep 50(RR 10) (2002): 1-25
7. "Smallpox vaccine adverse events among civilians--United States, March 4-10, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 201-3
8. "Product Information. Dryvax (smallpox vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
9. "From the Centers for Disease Control and Prevention. Smallpox vaccine adverse events among civilians--United States, February 18-24, 2003." JAMA 289 (2003): 1627-8
10. Bray M, Wright ME "Progressive vaccinia." Clin Infect Dis 36 (2003): 766-74
11. "Update on adverse events following civilian smallpox vaccination--United States, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 313-5
12. "Update: Adverse events following civilian smallpox vaccination--United States, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 360, 362-3
13. "Update: adverse events following civilian smallpox vaccination--United States, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 819-20
14. Talbot TR, Bredenberg HK, Smith M, LaFleur BJ, Boyd A, Edwards KM "Focal and generalized folliculitis following smallpox vaccination among vaccinia-naive recipients." JAMA 289 (2003): 3290-4
15. "Smallpox vaccine adverse events among civilians -- United States, February 25--March 3, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 180-1
16. "Update: adverse events following civilian smallpox vaccination--United States, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 475-7
17. Green JJ, Heymann WR "Dermatofibrosarcoma protuberans occurring in a smallpox vaccination scar." J Am Acad Dermatol 48(5 Suppl) (2003): S54-5
18. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA "Smallpox vaccination: a review, part II. Adverse events." Clin Infect Dis 37 (2003): 251-71
19. "Update: cardiac and other adverse events following civilian smallpox vaccination--United States, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 639-42
20. "Update: adverse events following civilian smallpox vaccination--United States, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 444-6
21. "Update: adverse events following smallpox vaccination--United States, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 278-82
22. "Update: adverse events following civilian smallpox vaccination--United States, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 419-20
23. "Update: Adverse events following civilian smallpox vaccination--United States, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 343-5
24. Bartlett J, Borio L, Radonovich L, et al. "Smallpox vaccination in 2003: key information for clinicians." Clin Infect Dis 36 (2003): 883-902
25. Hu G, Wang MJ, Miller MJ, et al. "Ocular vaccinia following exposure to a smallpox vaccinee." Am J Ophthalmol 137 (2004): 554-6
26. Vastag B "Experts weigh prevention, therapy for ocular vaccinia in smallpox vaccinees." JAMA 289 (2003): 2198-9
27. "Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices." MMWR Morb Mortal Wkly Rep 52 (2003): 282-4
28. Saurina G, Shirazi S, Lane JM, Daniel B, DiEugenia L "Myocarditis after smallpox vaccination: a case report." Clin Infect Dis 37 (2003): 145-6
29. "Update: cardiac-related events during the civilian smallpox vaccination program--United States, 2003." MMWR Morb Mortal Wkly Rep 52 (2003): 492-6
30. Whitman TJ, Ferguson MA, Decker CF "Cardiac dysrhythmia following smallpox vaccination." Clin Infect Dis 37 (2003): 1579-80
31. Maurer DM, Harrington B, Lane JM "Smallpox vaccine: contraindications, administration, and adverse reactions." Am Fam Physician 68 (2003): 889-96
32. "Cardiac deaths after a mass smallpox vaccination campaign--New York City, 1947." MMWR Morb Mortal Wkly Rep 52 (2003): 933-6
33. "Supplemental Recommendations on Adverse Events Following Smallpox Vaccine in the Pre-Event Vaccination Program: Recommendations of the Advisory Committee on Immunization Practices." JAMA 289 (2003): 2064
34. CDC Media Relations "Temporary deferral recommended for heart patients volunteering for smallpox vaccination. Available from: URL: http://www.cdc.gov/od/oc/media/pressure/r030325.htm." ([2003 Mar]):
35. Halsell JS, Riddle JR, Atwood JE, et al. "Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel." JAMA 289 (2003): 3283-9
More about Dryvax (smallpox vaccine)
- Other brands: ACAM2000
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.